Skip to content

Public FDA record

Z-1970-2010: Biokit HSV-2 Rapid test Catalogue Number: 3000-28001. 20 test Kit. In Vitro Diagnostic test for Herpe

Recall record Z-1970-2010 for Biokit U.S.A. Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1970-2010
Company in FDA record
Biokit U.S.A. Inc.
FDA classification date
Jul 8, 2010
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Negative serum was giving a positive result Herpes Simplex Type 2 (HSV-2). It is possible that misdiagnosis (i.e., positive) could be made.

Source facts

Action
Biokit USA notified US Customers by fax on 2/18/10 of the reason for the kit recall and requested to discard any remaining units. Accounts were advised to retest patients or review test results. Questions are directed to the firm at 800-926-3353.
Initiated
2010-04-14
Root cause
Nonconforming Material/Component
Terminated
2012-01-26
Distribution
US (CA, FL, GA, IN, KY, MA, NY, VA) and UK
Recall number
Z-1970-2010
Recall status
Terminated
CDRH record ID
90535
FDA classified
2010-07-08
Recall event number
55316

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗